NEVVI Medicare utilization intelligence

← back

HUYNH, CHANHMD NPI 1134324536 Clinician

Hematology-Oncology · YORK, PA

Specialty Hematology-Oncology — from billed Medicare claims
Trained STATE UNIVERSITY OF NEW YORK DOWNSTATE MEDICAL CENTER — medical school, self-reported to CMS
In practice about 22 years since medical school (class of 2004, self-reported to CMS)
Location YORK, PA · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 69 codes billed · 89,313 disclosed volume (CY2024 — most recent year in data)
Current groups

Group affiliation since 2019

20192026
CANCER CARE ASSOCIATES OF YORK, INC.
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2026-04

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Included with Platform.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Volume Beneficiary-episodes Avg charge Avg Medicare payment
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
J9271 Injection, pembrolizumab, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J9025 Injection, azacitidine, 1 mg
J9299 Injection, nivolumab, 1 mg
J0897 Injection, denosumab, 1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J1437 Injection, ferric derisomaltose, 10 mg
J1453 Injection, fosaprepitant, 1 mg
36415 Insertion of needle into vein for collection of blood sample
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
80053 Blood test, comprehensive group of blood chemicals
J9041 Injection, bortezomib, 0.1 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J0461 Injection, atropine sulfate, 0.01 mg
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
J2469 Injection, palonosetron hcl, 25 mcg
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
J1626 Injection, granisetron hydrochloride, 100 mcg
Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
83615 Lactate dehydrogenase (enzyme) level
J0640 Injection, leucovorin calcium, per 50 mg
J9190 Injection, fluorouracil, 500 mg
J9395 Injection, fulvestrant, 25 mg
J9206 Injection, irinotecan, 20 mg
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
96413 Administration of chemotherapy into vein, 1 hour or less
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
83735 Magnesium level
96372 Injection of drug or substance under skin or into muscle
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
84443 Blood test, thyroid stimulating hormone (tsh)
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
99211 Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional
96375 Injection of additional new drug or substance into vein
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
82728 Ferritin (blood protein) level
96415 Administration of chemotherapy into vein, each additional hour
84153 Psa (prostate specific antigen) measurement, total
83540 Iron level
83550 Iron binding capacity
96417 Administration of additional new drug or substance into vein, 1 hour or less
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
96361 Infusion into a vein for hydration, each additional hour
84550 Uric acid level, blood
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
82378 Carcinoembryonic antigen (cea) protein level
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
84100 Phosphate level
J1200 Injection, diphenhydramine hcl, up to 50 mg
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
J3489 Injection, zoledronic acid, 1 mg
96360 Infusion into a vein for hydration, 31-60 minutes
86300 Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
80048 Blood test, basic group of blood chemicals (calcium, total)
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
96411 Administration of additional new drug or substance into vein using push technique
J3490 Unclassified drugs
86301 Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9
99233 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes
96523 Irrigation of implanted venous access drug delivery device
99442 Telephone medical discussion with physician, 11-20 minutes
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.